Develops drugs for inflammatory and immune-mediated conditions.
Dec 2025Revenue $570K/yrExpenses $30.3M/yr
No trendCash runway ≈ 1.4 years from Jun 2026
Figures by year
When will Yarrow Bioscience be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $570K and expenses $30.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $570K | $30.3M | −$29.7M |
| Dec 2024 | $501K | $44.1M | −$43.6M |
| Dec 2023 | $424K | $29.7M | −$29.3M |
| Dec 2022 | $477K | $34.8M | −$34.3M |
| Dec 2021 | $931K | $39.8M | −$38.9M |
| Dec 2020 | $21.0M | $274M | −$253M |
| Dec 2019 | $443K | $96.3M | −$95.9M |
| Dec 2018 | $3.60M | $78.5M | −$74.9M |
| Dec 2017 | $4.58M | $34.2M | −$29.6M |
| Dec 2016 | $674K | $15.0M | −$14.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.